期刊文献+

伊达比星脂质体的制备及其包封率的测定 被引量:2

Preparation of idarubicin liposome and its entrapment efficiency determination
暂未订购
导出
摘要 目的制备伊达比星脂质体,建立伊达比星脂质体包封率的测定方法。方法采用薄膜分散.超声合并挤压法制备伊达比星脂质体,通过葡聚糖凝胶柱色谱分离游离药物和脂质体,用HPLCN定伊达比星含量,计算包封率。结果伊达比星脂质体平均包封率为65.42%,载药量为7.70%。凝胶柱色谱柱回收率99.76%,伊达比星在0.05-30.0μg/mL范围内线性关系良好(r=0.9999)。结论薄膜分散-超声合并挤压法适用于制备伊达比星脂质体,分析方法准确可靠可以用于伊达比星脂质体包封率的测定。 Objective To prepare idarubicin liposome and establish a method for determination of its entrapment efficiency. Methods The liposome was prepared by film dispersion-ultrasonic combined extrusion technique. The liposome and free idarubicin were separated by Sephadex-G50 chromatography. The concentration of idarubicin in the liposome was detected by HPLC, then the entrapment efficiency was evaluated. Results The mean entrapment efficiency of idarubicin liposome was 65.42% and the drug loading was 7.70%. The recovery rate was 99.76%. The standard curve was linear over the range of 0.05-30.0μg/mL with the correlation of 0.9999. Conclusion The film dispersion-ultrasonic combined extrusion technique is suitable for preparing idarubicin liposomes. This HPLC method was accurate and sensitive, and can be applied to the determination of idarubicin liposomes.
机构地区 成都大学
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2014年第6期447-450,共4页 Chinese Journal of Antibiotics
关键词 伊达比星 薄膜分散超声合并挤压法 脂质体 包封率 Idarubicin Film dispersion-ultrasonic combined extrusion technique Liposome Entrapment efficiency
  • 相关文献

参考文献4

二级参考文献47

  • 1[1]Smith PJ,Rackstraw C,Cotter F.DNA fragmentation as a consequence of cell cycle traverse in doxorubicin and idarubicin-treated human lymphoma cells[J].Ann Hematol,1994,69(suppl l):S7.
  • 2[2]Vial JP,Belloc F,Dumain P,et al.Study of the apoptosis induced in vitro by antitumoral drugs on leukemic cells[J].Leuk Res,1997,21(2):163.
  • 3[3]Roovers DJ,Van Vliet M,Bloem AC,et al.Idarubicin overcomes P-glycoprotein-related multidrug resistance:comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines [J].Leuk Res,1999,23(6):539.
  • 4[4]Fukushima T,Ueda T,Uchida M,et al.Action mechanism of idarubicin (4-demethoxydaunorubicin)as compared with daunorubicin in leukemic cells[J].Int J Hematol,1993,57:121.
  • 5[5]Wiernik PH,Banks PLC,Case DC,et al.Cytarabine plus idarubicin or daunorubicin as induction therapy and consolidation therapy for previously untreated adult patients with acute myeloid leukemia[J].Blood,1992,79:313.
  • 6[6]Musso M,Porretto F,Crescimanno A,et al.Low-dose long-term oral idarubicin in maintenance treatment of elderly acute myeloid leukemia[J].Haematologica,1997,82(suppl 5):4.
  • 7[7]Zwelling LA,Bales E,Altschuler E,et al.Circumvention of resistance by doxorubicin,but not by idarubicin,in a human leukemia cell line containing an intercalator-resistant form of topoisomeraseⅡ: evidence for a non-topoisomerase Ⅱ-mediated mechanism of doxorubicin cytotoxicity[J].Biothem Pharmacol,1993,45(2):516.
  • 8[8]Ketley NJ,Allen PD,Kelsey SM,et al.Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid,1, 25(OH)2 vitamin D3,and granulocyte-macrophage colony-stimulating factor[J].Blood,1997,90(11):4578.
  • 9[9]Musso M,Porretto F,Crescimanno A,et al.Only association of low concentrations of idarubicin plus idarbicinol induced apoptosis on leukemic cells[J].Leuk Res,1998,22:561.
  • 10[10]Vellon L,Cuello T,Gargallo P,et al.Antisense oligonucleotides increase the apoptotic effect of idarubicin in K562 cell line[J].Medicina, 2000, 60(1):143.

共引文献16

同被引文献14

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部